EudraCT

EudraCT - Axcellant

EudraCT

  1. lut 28, 2025

What Does the 'EudraCT’ Mean?

EudraCT stands for European Union Drug Regulating Authorities Clinical Trials. It is a database of all clinical trials conducted in the European Union (EU) since 2004. This centralized system was established to improve the oversight and transparency of clinical research within the EU.

The EudraCT database contains information on interventional clinical trials on medicinal products conducted in EU member states and the European Economic Area (EEA). It serves as a resource for regulatory authorities, healthcare professionals, and the public to access key details about ongoing and completed clinical trials in Europe.

Why Is the 'EudraCT’ Important in Clinical Research?

EudraCT plays a crucial role in ensuring transparency and regulatory compliance in European clinical trials. It provides a standardized platform for sponsors to register their studies, facilitating efficient communication with regulatory authorities and ethics committees across EU member states.

The system also enhances patient safety and public access to clinical trial information. By centralizing trial data, EudraCT enables better monitoring of ongoing studies, supports evidence-based decision-making in healthcare, and promotes collaboration among researchers in the European clinical research community.

Good Practices and Procedures

  1. Ensure all mandatory fields in the EudraCT application form are completed accurately, paying special attention to the consistency of information across related documents.
  2. Regularly update the EudraCT record with any significant changes to the trial protocol, including amendments, recruitment status, and safety information.
  3. Utilize the EudraCT number as a unique identifier in all trial-related communications with regulatory authorities and ethics committees to maintain consistency and traceability.
  4. Submit the clinical trial results to EudraCT within one year of the trial’s completion, adhering to the required format and level of detail specified in the guidance documents.
  5. Conduct periodic quality checks on the EudraCT data to ensure continued accuracy and completeness throughout the trial lifecycle.

Related Terms

Read more

Axcellant partners with Prometheus MedTech.AI to accelerate AI-powered cardiac diagnostics

We’re pleased to announce a strategic partnership between Axcellant and Prometheus MedTech.AI — a medtech startup developing AI-powered solutions for…

Axcellant at EANM 2025: What We Brought Back from Barcelona

The Axcellant team has returned from the European Association of Nuclear Medicine (EANM) Annual Congress in Barcelona — and it’s…

Radioisotopes in Medicine: Clinical Applications, Safety, and Regulatory Considerations

The robust development of nuclear medicine depends on the availability of radioactive isotopes, some of which are used for diagnostic…